Business News

Samsung BioLogics denies fraud allegations in South Korea listing

Ed Lane | Special to CNBC
Christ Ratcliffe | Bloomberg | Getty Images

Contract manufacturing firm Samsung BioLogics has denied allegations it juggled its accounting to show a surprise profit ahead of a listing last year on the South Korea stock exchange, saying a revaluation of its stake in biosimilar maker Samsung Bioepis was in line with accounting practices, The Korea Herald reported on Friday.

A South Korean legislator, Sim Sang-jeung, chairwoman of the minor opposition Justice Party and local civic group People's Solidarity for Participatory Democracy, suggested that Samsung BioLogics, which was unprofitable since starting operations in 2011 reported a net profit of 1.9 trillion won ($1.66 billion) in 2015 based on a revaluation of its holdings in the Samsung Bioepis unit in which US-based Biogen holds about 8 percent.

The listing of Samsung BioLogics in November last year was the second largest in on record and raised 2.25 trillion won ($1.97 billion).

Samsung BioLogics makes drugs for firms such as Swiss-based Roche under license, while it owns a stake of more than 90 percent of Samsung Bioepis, which makes biosimilars, versions of complex molecule drugs such as autoimmune disease therapy Enbrel.

Read the full report here.

Follow CNBC International on Twitter and Facebook.